Weiss Ratings Reiterates Sell (E+) Rating for 111 (NASDAQ:YI)

Weiss Ratings reaffirmed their sell (e+) rating on shares of 111 (NASDAQ:YI - Free Report) in a report published on Thursday,Weiss Ratings reports.

111 Trading Down 1.5 %

Shares of NASDAQ YI traded down $0.13 during midday trading on Thursday, reaching $8.27. 5,162 shares of the company were exchanged, compared to its average volume of 23,439. The stock has a fifty day simple moving average of $8.36 and a 200 day simple moving average of $7.41. The stock has a market cap of $70.73 million, a P/E ratio of -2.07 and a beta of 0.57. 111 has a 1 year low of $4.15 and a 1 year high of $14.10.

111 (NASDAQ:YI - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $527.14 million for the quarter.

Institutional Trading of 111

A number of hedge funds have recently added to or reduced their stakes in the business. FIL Ltd bought a new position in 111 during the 4th quarter valued at $450,000. JPMorgan Chase & Co. lifted its stake in shares of 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after acquiring an additional 305,339 shares during the period. Finally, Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in 111 during the fourth quarter worth about $245,000. 21.32% of the stock is owned by institutional investors and hedge funds.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.